Drug intelligence / Profile preview

ORYN1003

Development stage: Preclinical
Lead developer: Oryn Therapeutics
Modality: Peptides
Administration: Oral

Overview

ORYN1003 is a preclinical-stage, orally administered macrocyclic peptide developed by Oryn Therapeutics for the treatment of inflammatory and autoimmune diseases. It is a next-generation candidate derived from the company's proprietary Orynotide platform, which utilizes cyclic peptides to target allosteric control points on proteins involved in inflammatory and tissue-remodeling pathways. ORYN1003 is designed for once-daily (QD) oral dosing, incorporating optimization learnings from the company's earlier clinical program, ORTD-1.

Beyond the preview

Go deeper on ORYN1003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORYN1003.

Explore the full profile